Finanznachrichten

SuppreMol GmbH: SuppreMol's SM101 shows a sustained clinical activity and a favorable safety profile in Primary Immune Thrombocytopenia (ITP) patients

SuppreMol GmbH / SuppreMol's SM101 shows a sustained clinical activity and a favorable safety profile in Primary Immune Thrombocytopenia (ITP) patients . Processed and transmitted by Thomson Reuters ...
Finanznachrichten

SuppreMol GmbH: SuppreMol announces presentation of clinical data for its lead product SM101 at the 54th ASH Annual Meeting

SuppreMol GmbH / SuppreMol announces presentation of clinical data for its lead product SM101 at the 54th ASH Annual Meeting . Processed and transmitted by Thomson Reuters ONE. The issuer is solely ...
GEN

SuppreMol Taps Protagen’s Biomarker Expertise for Phase IIa Systemic Lupus Erythematosus Study

Deal covers identification of biomarkers of response to SuppreMol’s lead candidate SM101 SuppreMol is teaming up with Protagen to identify biomarkers of response to SuppreMol’s clinical-stage systemic ...
GEN

SuppreMol Wins $2.1M Funding for Clinical Development of Autoimmune Therapy

BMBF grant will facilitate Phase I trials of SM101 in SLE and preclinical studies in COPD. SuppreMol has been awarded €1.6 million ($2.1 million) in research funding from the German Federal Ministry ...
FierceBiotech

SuppreMol Employs Protagen Biomarkers in SLE Study

SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro ...